{
    "clinical_study": {
        "@rank": "139704", 
        "arm_group": {
            "arm_group_label": "BT524", 
            "arm_group_type": "Experimental", 
            "description": "Single intravenous infusion of a fixed dose of 70 mg BT524 per kilogram body weight (BW)"
        }, 
        "brief_summary": {
            "textblock": "The purpose of the study is to investigate pharmacokinetics, efficacy and safety of BT524 in\n      patients with congenital fibrinogen deficiency."
        }, 
        "brief_title": "Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Congenital Afibrinogenemia", 
            "Congenital Hypofibrinogenemia"
        ], 
        "condition_browse": {
            "mesh_term": "Afibrinogenemia"
        }, 
        "detailed_description": {
            "textblock": "The present study is designed as a prospective, open-label, multicentre, phase I/II study\n      investigating the 14 day single-dose pharmacokinetic properties, efficacy and  safety of\n      BT524 following intravenous administration in the treatment or prophylaxis of bleeding in\n      patients with congenital afibrinogenemia or severe congenital hypofibrinogenemia."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Congenital afibrinogenemia or severe congenital hypofibrinogenemia defined by  plasma\n             fibrinogen activity \u2264 0.5 g/l and antigen \u2264 0.5 g/l\n\n          -  Male or female\n\n          -  Age 6 to 75 years, with the first ten patients will be 18 years or older\n\n          -  Presumed to be compliant with the study procedures and to terminate the study as\n             scheduled\n\n          -  Willing and able to be hospitalized for 3 days for the pharmacokinetic assessment\n\n          -  Willing and able to be hospitalized - if required - in case of interventions (e.g.,\n             surgical procedures, major bleeds)\n\n          -  Written informed consent by the patient, his/her parents or by the patient's legal /\n             authorized representative as applicable\n\n        Exclusion Criteria:\n\n          -  Known congenital dysfibrinogenemia\n\n          -  Known bleeding disorder other than congenital fibrinogen deficiency\n\n          -  History of esophageal variceal bleeding\n\n          -  Known presence or history of venous/arterial thrombosis or thromboembolic event in\n             the preceding 6 months\n\n          -  Known presence or history of fibrinogen inhibitory antibodies\n\n          -  Known presence or history of hypersensitivity to human fibrinogen or human plasma\n             proteins e.g., immunoglobulins, vaccines or hypersensitivity to any of the excipients\n\n          -  Known positive serology for HIV-1 and HIV-2\n\n          -  Clinically relevant biochemical or hematological findings (except due to underlying\n             disease or emergency bleeding) outside the normal range (at the investigator's\n             discretion)\n\n          -  Clinically relevant pathological findings in physical examination including\n             electrocardiogram (ECG)\n\n          -  Treatment with any fibrinogen concentrate and/or fibrinogen-containing product within\n             2 weeks prior to infusion of BT524\n\n          -  Concomitant medication interacting relevantly with the coagulation system (e.g., low\n             molecular weight heparin, unfractioned heparin, factor Xa inhibitors, factor IIa\n             inhibitors or PY12 inhibitors) within 2 weeks prior to infusion of BT524\n\n          -  Recent vaccination (at least 3 weeks)\n\n          -  Body weight below 22 kg\n\n          -  End stage disease\n\n          -  Abuse of drugs\n\n          -  Unable to understand and follow the study requirements\n\n          -  Participation in another interventional clinical study within 30 days before entering\n             the study or during the study\n\n          -  Pregnant/ nursing woman, or woman of childbearing potential not using reliable/\n             effective contraceptive method(s) during the study and at least one month after the\n             last administration of study drug (e.g., oral/ injectable/ implantable/ insertable/\n             topical hormonal contraceptives, intrauterine devices, female sterilization,\n             partner's vasectomy or condoms)\n\n          -  Any other condition that, to the investigator's judgment, could have an impact on\n             patient's safety or the study results\n\n          -  Elective surgery during the 14 day PK blood sampling period\n\n          -  Acute infection\n\n          -  Clinically relevant increase or decrease in body temperature\n\n          -  Actively bleeding or anticipated bleeding (including female menorrhea) at the time\n             point of or within 7 days prior to infusion of BT524\n\n          -  Surgery within 7 days prior to infusion of BT524\n\n          -  Immobilization within 7 days prior to infusion of BT524\n\n          -  Intake of alcohol or significantly increased intake of caffeine containing products\n             within 24 hours prior to infusion of BT524\n\n          -  Blood donation or comparable blood loss within 60 days prior to infusion of BT524\n\n          -  Excessive physical exercise (extreme sports activities, sauna) within 72 hours prior\n             to infusion of BT524"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02065882", 
            "org_study_id": "Biotest 984", 
            "secondary_id": "2011-004154-25"
        }, 
        "intervention": {
            "arm_group_label": "BT524", 
            "description": "single intravenous infusion", 
            "intervention_name": "BT524 (fibrinogen concentrate from human plasma)", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "fibrinogen, bleeding,", 
        "lastchanged_date": "February 17, 2014", 
        "location": [
            {
                "contact": {
                    "email": "Claudia.khayat@yahoo.fr", 
                    "last_name": "Claudia Khayat, Dr", 
                    "phone": "+961 161 3027"
                }, 
                "facility": {
                    "address": {
                        "city": "Beirut", 
                        "country": "Lebanon"
                    }, 
                    "name": "Hotel Dieu de France Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "adlette.inati@lau.edu.lb", 
                    "last_name": "Adlette Inati, Dr", 
                    "phone": "00961 3 228033"
                }, 
                "facility": {
                    "address": {
                        "city": "Beirut", 
                        "country": "Lebanon"
                    }, 
                    "name": "Rafic Hariri University Hospital"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Lebanon"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Prospective, Open-label, Phase I/II Study Investigating Pharmacokinetic Properties of BT524 and Efficacy and Safety of BT524 in the Treatment and Prophylaxis of Bleeding in Patients With Congenital Fibrinogen Deficiency", 
        "overall_contact": {
            "email": "judith_wessels@biotest.de", 
            "last_name": "Judith Wessels-Kranz, PhD", 
            "phone": "+49 6103 801 6395"
        }, 
        "overall_contact_backup": {
            "email": "dorothee_schliephake@biotest.de", 
            "last_name": "Dorothee Schliephake, PhD", 
            "phone": "+49 (0) 6103 801-9804"
        }, 
        "overall_official": {
            "affiliation": "H\u00f4tel Dieu de France, Dept. of Pediatrics", 
            "last_name": "Claudia Djambas Khayat, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Lebanon: Ministry of Public Health", 
                "Italy: National Institute of Health", 
                "Germany: Paul-Ehrlich-Institut", 
                "Egypt: Ministry of Health and Population"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective of this study is to investigate the 14 day single-dose pharmacokinetics of BT524 following intravenous (IV) infusion in patients with congenital afibrinogenemia or severe congenital hypofibrinogenemia (part I).", 
            "measure": "Terminal Elimination Half-life (t1/2) for fibrinogen antigen,", 
            "safety_issue": "No", 
            "time_frame": "Prior to the initial dose on day 1, at the end of the infusion and 0.5, 1, 2, 4, 8 hours post dose,  24, 48,96, 168, 240h and 336 hours post-dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02065882"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Secondary objectives are to investigate the 14 day single-dose pharmacodynamics of BT524, and the surrogate efficacy and safety of BT524 in part I of the study. In addition, the hemostatic efficacy, surrogate efficacy, and safety of single and/or repetitive administrations for on-demand prophylaxis (ODP) and/or on-demand treatment (ODT) of bleeding events will be investigated.", 
            "measure": "Terminal Elimination Half-life (t1/2) for fibrinogen activity", 
            "safety_issue": "No", 
            "time_frame": "Prior to the initial dose on day 1, at the end of the infusion and 0.5, 1, 2, 4, 8 hours post dose, 24, 48,96, 168, 240 and 336 hours post-dose"
        }, 
        "source": "Biotest", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Aptiv Solutions", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Interlab", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Biotest", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}